AI Engines For more Details: Perplexity Kagi Labs You
Prevention of Accidental Ingestion: Denatonium benzoate is added to household products such as cleaning agents, antifreeze, and certain medications to make them unpalatable and discourage accidental ingestion, especially by children or pets. This helps prevent poisoning or other adverse effects resulting from the ingestion of potentially harmful substances.
Promotion of Safety: In industrial settings, denatonium benzoate may be used to denature ethanol or other products to prevent their misuse or unauthorized consumption. This is particularly important in industries where the safety of workers or the general public may be at risk if these substances are misused.
Avoidance of Ingestion: Denatonium benzoate may also be added to products like nail polishes or bitter-tasting sprays used to deter nail-biting or thumb-sucking habits in children. By making these products taste extremely bitter and unpleasant, it encourages individuals to avoid putting them in their mouths.
Potential for Skin and Eye Irritation: While denatonium benzoate is generally considered safe when used as intended, direct contact with concentrated solutions or undiluted products containing this compound may cause skin or eye irritation. It is important to handle products containing denatonium benzoate with care and to avoid contact with sensitive areas.
Limited Health Impact: When used as directed and in appropriate concentrations, denatonium benzoate is unlikely to cause significant health impacts. However, ingestion of large amounts may lead to nausea, vomiting, or other gastrointestinal discomfort due to its intensely bitter taste.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | 0.3 | |
| ADHD | 0.8 | 0.3 | 1.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergies | 0.3 | 0.4 | -0.33 |
| Allergy to milk products | 0.3 | 0.3 | |
| Alzheimer's disease | 0.8 | 1.3 | -0.63 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | |
| Ankylosing spondylitis | 0.1 | 0.3 | -2 |
| Anorexia Nervosa | 0.5 | -0.5 | |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | 0 |
| Asthma | 0.8 | 0.5 | 0.6 |
| Atherosclerosis | 0.3 | 0.9 | -2 |
| Atrial fibrillation | 0.3 | 0.4 | -0.33 |
| Autism | 1.2 | 1.5 | -0.25 |
| Autoimmune Disease | 0.5 | -0.5 | |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| Biofilm | 0.2 | 0.2 | |
| Bipolar Disorder | 0.3 | 0.8 | -1.67 |
| Brain Trauma | 0.5 | -0.5 | |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 0.3 | 0.1 | 2 |
| Carcinoma | 0.8 | 0.8 | |
| Celiac Disease | 0.3 | 0.3 | 0 |
| Cerebral Palsy | 0.5 | -0.5 | |
| Chronic Fatigue Syndrome | 0.3 | 0.8 | -1.67 |
| Chronic Kidney Disease | 1.1 | -1.1 | |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 1.1 | -0.83 |
| Chronic Urticaria (Hives) | 0.1 | -0.1 | |
| Coagulation / Micro clot triggering bacteria | 0.5 | -0.5 | |
| Cognitive Function | 0.5 | 0.5 | 0 |
| Colorectal Cancer | 1.1 | 0.5 | 1.2 |
| Constipation | 0.5 | -0.5 | |
| Coronary artery disease | 0.8 | -0.8 | |
| COVID-19 | 0.3 | 1.2 | -3 |
| Crohn's Disease | 1.7 | 1.1 | 0.55 |
| cystic fibrosis | 0.5 | -0.5 | |
| deep vein thrombosis | 1.1 | 0.5 | 1.2 |
| Denture Wearers Oral Shifts | 0.2 | 0.2 | |
| Depression | 1.6 | 1.6 | 0 |
| Eczema | 0.3 | 0.3 | |
| Endometriosis | 0.3 | 0.8 | -1.67 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | |
| Epilepsy | 0.3 | 0.3 | |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.5 | 0.4 | 0.25 |
| Functional constipation / chronic idiopathic constipation | 0.6 | 0.9 | -0.5 |
| gallstone disease (gsd) | 0.8 | -0.8 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.5 | |
| Generalized anxiety disorder | 0.6 | 0.3 | 1 |
| Gout | 0.3 | -0.3 | |
| Graves' disease | 0.8 | -0.8 | |
| Gulf War Syndrome | 0.3 | 0.3 | |
| Halitosis | 0.5 | 0.5 | |
| Hashimoto's thyroiditis | 0.8 | 0.3 | 1.67 |
| Heart Failure | 0.5 | 0.5 | 0 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1.1 | -1.1 | |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.1 | -0.1 | |
| IgA nephropathy (IgAN) | 0.3 | 0.6 | -1 |
| Inflammatory Bowel Disease | 0.5 | 1.7 | -2.4 |
| Insomnia | 0.3 | 0.5 | -0.67 |
| Intelligence | 0.3 | 0.1 | 2 |
| Intracranial aneurysms | 0.3 | 0.3 | 0 |
| Irritable Bowel Syndrome | 0.8 | 0.8 | 0 |
| ischemic stroke | 0.5 | -0.5 | |
| Liver Cirrhosis | 1.4 | 1.4 | 0 |
| Long COVID | 0.7 | 1.4 | -1 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.2 | 0.3 | -0.5 |
| ME/CFS with IBS | 0 | 0.3 | 0 |
| Menopause | 0.5 | -0.5 | |
| Metabolic Syndrome | 1.5 | 1.4 | 0.07 |
| Mood Disorders | 1.6 | 1.3 | 0.23 |
| Multiple Sclerosis | 0.6 | 0.9 | -0.5 |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 0.5 | -0.5 | |
| Neuropathy (all types) | 0.5 | -0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.9 | 0.8 | 0.13 |
| Obesity | 1.5 | 1.5 | 0 |
| obsessive-compulsive disorder | 0.4 | -0.4 | |
| Osteoporosis | 0.5 | 0.5 | |
| pancreatic cancer | 0.2 | 0.2 | |
| Parkinson's Disease | 1.1 | 1.5 | -0.36 |
| Polycystic ovary syndrome | 1.1 | 0.8 | 0.38 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| primary biliary cholangitis | 0.3 | -0.3 | |
| Primary sclerosing cholangitis | 0.3 | 0.3 | 0 |
| Psoriasis | 0.9 | -0.9 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.4 | 1.1 | 0.27 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 0.9 | 0.8 | 0.13 |
| scoliosis | 0.3 | 0.3 | 0 |
| Sjögren syndrome | 0.1 | 0.1 | |
| Sleep Apnea | 0.6 | 0.8 | -0.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 0.8 | 0.8 | 0 |
| Systemic Lupus Erythematosus | 0.9 | 0.5 | 0.8 |
| Tic Disorder | 0.1 | -0.1 | |
| Type 1 Diabetes | 0.6 | 0.5 | 0.2 |
| Type 2 Diabetes | 1.5 | 1.1 | 0.36 |
| Ulcerative colitis | 0.3 | 1.2 | -3 |
| Unhealthy Ageing | 1.2 | 0.8 | 0.5 |
| Vitiligo | 0.3 | -0.3 |
